Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Progression-free survival (PFS)

This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy
 after initial treatment for nasopharyngeal cancer that has come back after a period of
 improvement (recurrent) or that has spread from where it first started (primary site) to
 other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere
 with the ability of tumor cells to grow and spread. The usual approach of treatment is
 initial treatment with chemotherapy such as the combination of cisplatin (or carboplatin) and
 gemcitabine, along with immunotherapy such as nivolumab. After the initial treatment is
 finished, patients may continue to receive additional immunotherapy. Carboplatin is in a
 class of medications known as platinum-containing compounds. It works in a way similar to the
 anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by
 killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal
 antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may
 interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy
 drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells.
 Giving BMS-986016 in addition to the usual immunotherapy after initial treatment may extend
 the time without the tumor cells grow or spread longer than the usual approach in patients
 with recurrent or metastatic nasopharyngeal cancer.